Klingelhuber, Felix http://orcid.org/0000-0002-0034-6170
Frendo-Cumbo, Scott http://orcid.org/0000-0002-9047-4650
Omar-Hmeadi, Muhmmad http://orcid.org/0000-0001-8893-7348
Massier, Lucas http://orcid.org/0000-0002-6199-2643
Kakimoto, Pamela http://orcid.org/0000-0002-7471-3850
Taylor, Austin J. http://orcid.org/0000-0001-8167-1209
Couchet, Morgane http://orcid.org/0000-0003-3851-8529
Ribicic, Sara
Wabitsch, Martin http://orcid.org/0000-0001-6795-8430
Messias, Ana C. http://orcid.org/0000-0002-5449-9922
Iuso, Arcangela
Müller, Timo D.
Rydén, Mikael http://orcid.org/0000-0003-4785-1876
Mejhert, Niklas http://orcid.org/0000-0003-1785-833X
Krahmer, Natalie http://orcid.org/0000-0003-4063-7367
Article History
Received: 30 June 2023
Accepted: 7 March 2024
First Online: 2 April 2024
Competing interests
: T.D.M. receives research funding from Novo Nordisk and has received speaking fees from Eli Lilly, AstraZeneca and Novo Nordisk. The other authors declare no competing interests.